GlassScriptPhysician profile
Inna Sominsky
NPI 1649463522
$2,532.84
in general payments reported to CMS, 2019-2025
38 companies · $684 in 2025
The $684 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $468 · 2021: $362 · 2022: $158 · 2023: $188 · 2024: $408 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.96 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $372.76 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $291.92 | 2020-2025 | Tecvayli, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $216.84 | 2020-2025 | Calquence |
| Pharmaessentia USA Corporation | $156.96 | 2025 | Besremi |
| Pfizer INC. | $148.94 | 2019-2025 | |
| Astellas Pharma US INC | $139.59 | 2023-2024 | Xtandi |
| Celgene Corporation | $131.98 | 2021-2025 | Reblozyl |
| Amgen INC. | $110.84 | 2020-2022 | |
| Sobi, INC | $89.99 | 2025 | |
| Shield Therapeutics INC | $74.93 | 2023-2025 | Accrufer |
| Seagen INC. | $63.51 | 2020-2022 | |
| Abbvie INC. | $62.64 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $59.16 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $53.06 | 2020-2025 | Keytruda, Welireg, Keytruda Qlex |
| Lilly USA, LLC | $46.35 | 2020-2024 | Retevmo, Jaypirca, Verzenio |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $41.52 | 2020-2021 | |
| Exelixis INC. | $29.20 | 2022 | |
| Deciphera Pharmaceuticals INC. | $27.16 | 2025 | Qinlock, Tgct |
| Incyte Corporation | $26.93 | 2025 | Jakafi, Monjuvi, Zynyz |
| Kite Pharma, INC. | $26.35 | 2019 | |
| Glaxosmithkline, LLC. | $26.24 | 2025 | Ojjaara |
| Spectrum Pharmaceuticals INC. | $24.90 | 2024 | Rolvedon |
| Mirati Therapeutics, INC. | $24.29 | 2023 | Krazati |
| Clovis Oncology, INC. | $23.32 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.08 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $22.39 | 2019 | |
| Emd Serono, INC. | $21.81 | 2025 | |
| Agios Pharmaceuticals, INC. | $21.53 | 2025 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $20.79 | 2020 | |
| Acceleron Pharma, INC. | $20.71 | 2020 | |
| G1 Therapeutics, INC. | $20.43 | 2023 | Cosela |
| Puma Biotechnology, INC. | $19.66 | 2024 | |
| Ge Healthcare | $19.16 | 2022 | |
| Gilead Sciences, INC. | $16.67 | 2019 | |
| Daiichi Sankyo INC. | $16.58 | 2022 | |
| Eisai INC. | $15.01 | 2021 | |
| Coherus Oncology, INC. | $14.20 | 2021 | |
| Tersera Therapeutics LLC | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Sominsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.